Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

About this update from Tempus Ai, Inc.

[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nTempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary eyonis® LCS to the Tempus Pixel platform. This collaboration empowers clinical workflows with a powerful tool to support informed diagnostic and disease management decisions.\n\n\nAccording to a study by the American Cancer Society, only about 20% of eligible individuals in the U.S. were screened for lung cancer in 2024. Closing the gap and achieving full participation among eligible individuals could prevent an estimated 62,110 lung cancer deaths over five years. eyonis® LCS is an AI-based CADe/CADx software as a medical device (SaMD) for lung cancer screening. It enables clinicians to not only detect lung nodules but also characterize and risk stratify them from the same CT image without additional steps in the workflow. eyonis® LCS received 510(k) clearance from the U.S. Food and Drug Administration (FDA) earlier this month.\n\n\nThrough this collaboration, Tempus will integrate eyonis® LCS into Tempus Pixel1, an FDA-cleared, CE-marked AI-enabled solution that provides advanced analysis, tools, and automated reporting from radiology images to help providers accurately track and quantify lesions. The integration of eyonis® LCS will enable non-invasive characterization of CT identified lung nodules at the time of nodule detection with its proprietary nodule malignancy score, a feature that will allow clinical teams to stratify and prioritize patients in lung cancer screening programs.\n\n\n“Activating our distribution collaboration with Tempus AI is a decisive step in bringing eyonis® LCS to patients at national scale,” said Fredrik Brag, CEO and Founder of Median Technologies. “Tempus’ strong leadership in AI-enabled precision medicine, deeply integrated data-technology ecosystem, and strong market presence make them an exceptional partner to drive rapid and high-impact adoption of eyonis® LCS across the United States.”\n\n\n“We believe AI reaches its full potential when it helps clinicians identify disease earlier and more accurately,” said Razik Yousfi, Tempus SVP & GM, AI Products. “By expanding our Pixel platform with sophisticated lung cancer screening AI tools, we are enabling radiologi...

More updates from Tempus Ai, Inc.